This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Cell Therapeutics Still Has Heavy Debt Load

Stocks in this article: CTIC

Cell Therapeutics (CTIC) removed a sizeable chunk of its debt burden, but much still remains hanging over the company's head.

Holders of 46% of Cell Therapeutics' nearly $119 million in convertible debt agreed to tender their notes in exchange for cash and common stock, the Seattle-based drug developer said Wednesday.

The preliminary results of the debt tender offer, which expired Tuesday night, cuts the company's debt burden by $54.8 million and will reduce future annual interest expenses by $3.4 million.

But holders of more than half of Cell Therapeutics' debt chose not to accept the company's below-par bid for their notes, which means the company remains in shaky financial straits.

To put the 46% acceptance figure in perspective, Cell Therapeutics was aiming to convince 70% of note holders to agree to the debt tender offer in May, before the company raised its exchange offer earlier this month.

The $64 million in debt still on Cell Therapeutics' books includes $43 million in notes due in 2010. Only 30% of the 2010 holders agreed to tender their notes.

Cell Therapeutics will pay out $7.4 million in cash and 25.1 million shares of company stock to satisfy those note holders who accepted the debt tender offer.

Previously, Cell Therapeutics warned that its remaining cash was only sufficient to fund the company through August. Recent cost-cutting measures and the partial easing of interest payments may extend that cash further, but it's not clear by how long because the company didn't update its financial guidance Wednesday.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs